iSpecimen Inc
ispecimen.comWhat Do They Do?
Connects life science researchers with human biospecimens and associated data through an online marketplace, serving biopharmaceutical companies, diagnostic companies, and government and academic institutions.
10-K for FY2025, filed Apr 1, 2026iSpecimen is technology-driven company founded to address a critical challenge: how to connect life science researchers who need human…View ↗
The iSpecimen Marketplace brings new capabilities to a highly fragmented and inefficient biospecimen procurement market. Our technology…View ↗
Our CustomersView ↗
How Do They Make Money?
Researchers pay iSpecimen for specimens it procures from healthcare providers and delivers after an order; the company shares part of that revenue with the supplying organizations.
10-K for FY2025, filed Apr 1, 2026 10-K for FY2022, filed Mar 21, 2023The iSpecimen Marketplace currently supports the supply chain management and bioprocurement process for specimens and associated data. We…View ↗
The iSpecimen Marketplace currently supports the supply chain management and bioprocurement process for specimens and associated data. We…View ↗
-
10-K for FY2025, filed Apr 1, 2026
FY2025 revenue by product or service ↗
$1.9M
-
10-K for FY2025, filed Apr 1, 2026
$1.9M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Specimens - contracts with customers
Sold outright
10-K for FY2025, filed Apr 1, 2026 |
90%
FY2022: 96%
|
Specimens - contracts with customers, FY2025
$1.7M Sources
|
Sold outright |
|
Shipping and other
|
10%
FY2022: 4.3%
|
Shipping and other, FY2025
$194K Sources
|
Who Are Their Customers?
10-K for FY2025, filed Apr 1, 2026
For the year ended December 31, 2025, one customer (Customer A) accounted for approximately 19.57% of the Company’s total revenues. For the…View ↗
Do Revenues Turn Into Profits?
No. It lost $10.5M in FY2025.
10-K for FY2025, filed Apr 1, 2026
−$9MView ↗
10-K for FY2025, filed Apr 1, 2026
−$10.5MView ↗
10-K for FY2025, filed Apr 1, 2026
−$4.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.4MView ↗
- ▲ +30% (Loss)
- vs −$1M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 14, 2026
Open tableView ↗
-
Sep 8, 2026
Received more time to meet Nasdaq’s stockholders’ equity rule
Nasdaq extended the deadline to demonstrate compliance until November 25, 2026.
Sources
8-K, filed Sep 10, 2026
Based on the Submission, Nasdaq granted the Company an extension until November 25, 2026 to evidence compliance with the Rule. On or before…View ↗
-
Sep 4, 2026
Agreed to acquire AI software and related assets
The proposed purchase includes tools for protein discovery and disease-trend prediction; closing requires stockholder approval.
Sources
8-K, filed Sep 4, 2026
On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”)…View ↗
-
Aug 31, 2026
Appointed a new CEO after the prior CEO chose to transition
Shahin Behroyan was appointed CEO after Katharyn Field informed the board of her decision to transition from the role.
Sources
8-K, filed Aug 31, 2026
On August 26, 2026, Katharyn Field informed the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) of her decision to…View ↗
Who Do They Compete With?
Competes with Discovery Life Sciences, StemExpress, and Science Exchange
10-K for FY2025, filed Apr 1, 2026Specimen providers (e.g. Discovery Life Sciences and StemExpress) maintain internal biobanks and enable researchers to search online for…View ↗
Loading...
